ROCHE

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Research, Bayer, IND, Clostridioides difficile infection, Ovarian cancer, Hemangioma, FAP, Therapy, H100, Foundation models, Genetics, PB, SALT, Exercise, Software, Development, NF2, Pharmacokinetics, APC, NVIDIA, Clinical trial, Biology, Drug discovery, CCM, Partnership, Machine learning, Recursion, Meningioma, Personalized medicine, Benchmarking, LILAC, AXIN1, Genentech, Safety, Chemistry, Patient, Biotechnology, Map, Administration, Video game, Pharmaceutical industry, Fine chemical, Tempus

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, PKU, Patent, AbbVie, PAL, International Conference on Nuclear Disarmament, Oslo, 2008, Homocystinuria, Treatment, University, Conference, Progress, Phenylketonuria, Partnership, Head, United States patent law, Methionine, Lead, Pittsburgh, Investment, Inflammatory bowel disease, Nature Metabolism, Nursing, Pharmaceutical industry, Cryptocurrency, Vitro

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • Publication of Synpheny-1 Phase 2 study results for the PKU program in the journal Nature Metabolism.
  • Presentation of Synpheny-1 Phase 2 study results by lead investigator Dr. Jerry Vockley of the University of Pittsburgh at the 37th E.S.PKU Conference 2023.
  • Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022.
  • General and administrative expenses were $3.4 million for the three months ended September 30, 2023, compared to $4.4 million for the corresponding period in 2022.

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Hepatocyte, Prostate-specific antigen, Research, Trial of the century, IND, PSA, Infection, Hepatitis, Pembrolizumab, Head, HIV, Liver, KRAS, Arenavirus, Prostate cancer, Gilead Sciences, Journal, CPI, Development, Gilead, Lung, PAP, Oncology, Serum, Safety, European Society of Gynaecological Oncology, Cancer, Patient, Administration, HBV, The Journal of Infectious Diseases, Investigational New Drug, Pharmaceutical industry, Clothing, Vaccine, Reinsurance

With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.

Key Points: 
  • With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
  • Enrollment continued in the ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
  • HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
  • The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023.

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Week, Patient, FDA, Research, Disposable household and per capita income, Standard of care, Immunodeficiency, SOC, Ageing, Bemnifosbuvir, Income tax, Food, RNA, Viral, Fast Track, Hepatitis C, Cirrhosis, BID, Doctor of Philosophy, Infection, Regulation of tobacco by the U.S. Food and Drug Administration, Development, Risk, Clinical trial, Atea, COVID-19, HCV, Security (finance), SVR, Second generation, Safety, Virological failure, Hospital, Administration, Death, Pharmaceutical industry, Cryptocurrency

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • We’ve quickly completed enrollment of the   60-patient lead-in cohort and initial results are expected in early 2024," continued Dr. Sommadossi.
  • Currently, Atea anticipates providing an update after each of these interim analyses are completed with the first update expected to occur in the first quarter of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $595.1 million at September 30, 2023 compared to $608.1 million at June 30, 2023.
  • Income Tax Expense: Income tax expense was $0.2 million for the quarter ended September 30, 2023 compared to a benefit of $3.8 million for the quarter ended September 30, 2022.

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Retrieved on: 
Tuesday, November 7, 2023
FDA, Janssen, Organon, G&A, Inflammation, Place of birth, NDA, License, End-user license agreement, Glioma, Video game, Cryptocurrency, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent portfolio activities expected to drive long-term shareholder value.

Key Points: 
  • XOMA recorded total revenues of $0.8 million for the third quarter of 2023 and $0.5 million for the third quarter of 2022.
  • General and administrative (“G&A”) expenses were $6.4 million for the third quarter of 2023, compared to $4.8 million for the third quarter of 2022.
  • In the third quarter of 2023, G&A expenses included $2.7 million in non-cash stock-based compensation expense, compared with $0.8 million in the third quarter of 2022.
  • Other income, net was $0.3 million for the third quarter of 2023 and $0.2 million in the corresponding quarter of 2022.

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Amyloid, Survival, FDA, Bristol Myers Squibb, Research, Organ dysfunction, AD, IND, PD, Food, VITAL, ATTR, Therapy, Fast track (FDA), AL, Mortality, G&A, Novo Nordisk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acquisition, European Medicines Agency, American Society of Hematology, MAD, SAD, Orphan, R, TTR, ASH, Clinical trial, Biology, Risk, Alpha-synuclein, Epitope, Amyloidosis, Society, SPA, Patient, Failure, Pharmaceutical industry, Vaccine, Fine chemical, Security (finance), Blood

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.
  • Robust reduction of brain amyloid plaque has been demonstrated to likely predict clinical benefit for people with early AD.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PRX012 for the treatment of AD.
  • As of September 30, 2023, Prothena had $673.1 million in cash, cash equivalents and restricted cash, and no debt.

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, FDA, Pharmaceutical, Health, Sino-Japanese Journalist Exchange Agreement, Priority review, Research, Sale, LGMD, Hart–Scott–Rodino Antitrust Improvements Act, PMOS, Patent, Food, PIN, Rare, RNA, GAAP, PRV, SRPT, Acquisition, Holocene, Sarepta Therapeutics, Food and Drug Administration, Disease, Interest, Clinical trial, Duchenne, Duchenne muscular dystrophy, University, Nationwide Children's Hospital, Depreciation, Leyland Royal Tiger PSU, BioMarin Pharmaceutical, Therapy, Investment, Patient, Hospital, Pharmaceutical industry, Reinsurance, Cryptocurrency, Fine chemical, Rare-earth element, Airline, Property management, Bank, Real estate, Life insurance, Note

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.
  • Total net product revenue stands at $309.3 million, growing 49 percent over the same quarter last year.
  • These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Patient Engagement in Clinical Trials: Beyond Recruitment to Long-Term Success, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 1, 2023
Consultant, Psychology, Innovation, British Pregnancy Advisory Service, Associate Director of National Intelligence and Chief Information Officer, Research, Trust, Clinical trial, BYOD, Telehealth, Safety, Patient, Role, Pharmaceutical industry

TORONTO, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Are you looking to revolutionize your approach to clinical trials? Join the featured speakers for an enlightening panel discussion on "Patient Engagement in Clinical Trials: Beyond Recruitment to Long-Term Success." In this dynamic webinar, industry experts will explore the transformative power of actively engaging patients throughout the entire clinical trial lifecycle.

Key Points: 
  • In this free webinar, gain insights into the evolving landscape of patient engagement in clinical trials.
  • Join the featured speakers for an enlightening panel discussion on "Patient Engagement in Clinical Trials: Beyond Recruitment to Long-Term Success."
  • In this dynamic webinar, industry experts will explore the transformative power of actively engaging patients throughout the entire clinical trial lifecycle.
  • Benefits of Holistic Patient Engagement: Our esteemed panelists will explore the manifold advantages of engaging patients throughout the clinical trial journey.

Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses

Retrieved on: 
Thursday, October 26, 2023
Digital, Laboratory, Research, Incidence, ROG, IVD, Marie Cassidy, RO, Pathology, Amazon Web Services, Health, Artificial intelligence, Ibex, Collaboration, Ecosystem, Hospital, Digital pathology, AWS, Algorithm, Cancer, AI, Breast, Diagnosis, Medical imaging

Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.

Key Points: 
  • Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.
  • Digital pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis.
  • Digital pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and providing an opportunity for collaboration in pathology workflows.
  • "This exciting collaboration brings powerful AI solutions to pathology labs," said Michael Rivers, Lifecycle Leader for Roche Digital Pathology.

Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses

Retrieved on: 
Thursday, October 26, 2023
Digital, Laboratory, Research, Incidence, ROG, IVD, Marie Cassidy, RO, Pathology, Amazon Web Services, Health, Artificial intelligence, Ibex, Collaboration, Ecosystem, Hospital, Digital pathology, AWS, Algorithm, Cancer, AI, Breast, Diagnosis, Medical imaging

Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.

Key Points: 
  • Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.
  • Digital pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis.
  • Digital pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and providing an opportunity for collaboration in pathology workflows.
  • "This exciting collaboration brings powerful AI solutions to pathology labs," said Michael Rivers, Lifecycle Leader for Roche Digital Pathology.